Search

Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with ≥2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting. Clinical Trial Registration: NCT03306394 ( ClinicalTrials.gov )

As with other solid tumors, comprehensive geriatric assessment should be performed before the treatment of GI system cancers. Chronological age alone is not a contraindication to treatment. Physiological age and performance status are more important. Healthy elderly patients without comorbidity benefit from treatment as much as young people. In patients with comorbidity, the dose may be reduced or a single agent may be preferred for cytotoxic treatments. In these cases, side effect monitoring and management gains importance. This section summarizes the characteristics of management and treatment of digestive system cancers in the elderly population. WOS:000773800000013